Objective: The menopausal transition (MT) is a critical period associated with physiologic changes that influence women's long-term health and longevity. Information is, however, limited regarding factors that influence age at the onset of the MT and its duration (ie, time from MT onset to the final menstrual period).
T he menopausal transition (MT), a critical period of physiologic change, is associated with transitory symptoms, such as hot flashes and depressive symptoms, [1] [2] [3] and persistent changes in bone density and lipids. [4] [5] [6] Improving prediction of when the MT starts and who will have a shorter or longer transition would answer one of the questions midlife women most often ask clinicians and assist in decision making regarding symptom management and timing of screening and interventions to address bone loss, adverse changes in cardiovascular risk, and abnormal uterine bleeding and menopausal symptoms. Several studies have documented risk factors associated with age at the final menstrual period (FMP). [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Only a few have elucidated factors that influence menstrual characteristics 18, 19 or hormonal patterns [20] [21] [22] during the MT. Despite the importance of predicting when the MT will start and how long it will last, data addressing these questions are limited. In his landmark menstrual calendar study, Treloar estimated the median duration of the MT in white college-educated women to be 4.8 years. 23 Recent prospective studies have used interviews and questionnaires 15, [24] [25] [26] to estimate both age-at-onset and duration of the MT. Menstrual calendars, however, remain the preferred method as questionnaires poorly identify the start of the MT. 27 Analyzing prospectively collected menstrual calendar data from the Study of Women's Health Across the Nation (SWAN), we examined the association of race/ethnicity, current smoking, body mass index (BMI), menstrual history, and socioeconomic status with the timing of onset and duration of the early and late MT.
METHODS

Study population
This analysis included women from the four SWAN sitesBoston, southeastern Michigan, Los Angeles, and Oakland, CA-that had appropriate menstrual calendar data. The design of SWAN has been previously described. 28 Briefly, eligibility for enrollment into the cohort study included age 42 to 52 years, self-designation as a member of the targeted racial/ethnic groups, residence in the geographic area of one of the sites, the ability to speak English, Cantonese, or Japanese, an intact uterus and at least one ovary, not pregnant or lactating, and at least one menstrual period and no use of reproductive hormones in the previous 3 months. Each site recruited white women and women from one specified minority group (African Americans in Boston and southeastern Michigan, Japanese in Los Angeles, and Chinese in Oakland). Institutional Review Boards at each study site approved the protocol, and all participants gave written informed consent.
Of the 1,852 women enrolled in the SWAN menstrual calendar study at the four study sites, the onset of the early MT was not observed in 705 women as 252 women were already in early transition at the time of enrollment and 453 women contributed fewer than 10 untreated menstrual cycles. These 705 women and the 2 women who were missing information on education were excluded. Thus, 1,145 women (61.8%) were eligible for analysis.
Data collection
Enrollment began in 1996 with approximately annual follow-up visits and a menstrual calendar component that continued through 2006, corresponding to the 10th follow-up visit. Each visit consisted of questionnaires that inquired about a broad range of topics, including information on menstrual experiences, sociodemographic characteristics, lifestyle, and medical history. Participants completed menstrual calendars daily to record any spotting or bleeding. On the last day of the month, women indicated if no bleeding occurred that month and answered questions about use of oral contraceptives, hormone therapy (HT), or gynecological procedures. Women were asked to complete the menstrual calendar until 2 years after their final menstrual bleed or hysterectomy.
Menopausal stage
Women's menstrual experience was assessed by their sequence of menstrual cycle lengths, calculated using bleeding definitions recommended by the World Health Organization 29 as adapted by the ReSTAGE Collaboration for midlife women. 30 A menstrual cycle consisted of a bleeding episode and a subsequent bleed-free interval of at least 3 days. The onset of the early MT was defined from the calendar data using the STRAWþ10 31 criteria: a persistent difference of at least 7 days in the length of consecutive menstrual cycles with persistence defined as recurrence within 10 cycles of the first variable length cycle. The onset of the late transition was defined as the first occurrence of a menstrual cycle length of at least 60 days. The FMP was defined as the bleeding episode followed by at least 12 months of amenorrhea.
Covariates
HT use, including menopausal HT, oral contraceptives, or chemotherapy, was ascertained each month on the menstrual calendar. For each menstrual cycle, measured weight was linearly interpolated between the last and next annual visits. BMI, weight in kilograms divided by height in meters squared, was categorized as normal (24.9 kg/m 2 ), overweight (25.0-29.9 kg/m 2 ), or obese (30.0 kg/m 2 ). At each annual visit, women reported whether they smoked currently (>1 cigarette/d). If a woman indicated she was a current smoker, all menstrual cycles during the prior year were classified as smoking. Smoking was categorized as current smoker (yes/no) as timing and duration of former smokers did not differ from nonsmokers.
At baseline, women indicated their usual menstrual cycle length and whether they had unpredictable menstrual cycles at ages 25 to 30 years; self-defined race/ethnicity (African American, Japanese, Chinese, or white); highest educational level achieved (less than high school, high school, or at least some college); presence of economic strain (how hard is it to pay for basics: very hard, somewhat hard, or not hard).
Statistical analyses
Frequency distributions were calculated for covariates. We used Cox proportional hazards 32 models to determine the association between potential risk factors and age at the onset of the MT, duration of the early MT stage (time from the onset of the early MT to the onset of the late MT), duration of the late MT stage (time from the onset of the late MT to FMP), and total duration of the MT (time from the onset of the early MT to FMP). Smoking status and BMI were defined by women's status at the onset of the MT when modeling age at start of the transition and the duration of the early and late transition and by her status at the onset of the late MT when modeling duration of the late transition. Kaplan-Meier DURATION OF THE MENOPAUSAL TRANSITION survival curves were generated to graph the timing and length of each transition stage, adjusting for confounding variables.
The proportional hazards assumption for each of the predictors was checked graphically with none violating this assumption. Women were censored at the time of hysterectomy, bilateral oophorectomy, or chemotherapy, or if they started continuous HT use and had no subsequent untreated cycles. Pregnancy, periods of HT use, and missing calendars were treated as gaps in the menstrual history, with the assumption that staging events did not occur during gaps based on our prior work showing this assumption had little impact on estimated timing of menopausal stages. 33 Statistical analyses were performed using SAS 9.2 (SAS Institute Inc, Cary, NC).
RESULTS
Baseline characteristics of the study population are shown in Table 1 . In total, 1,145 of the 1,852 women participating in the menstrual calendar substudy were eligible for this analysis. Eligible women were more likely to be Chinese or Japanese and, consequently, to be from Oakland or Los Angeles, to be of normal weight and nonsmokers, to have graduated from college, and to find it not hard to pay for basics compared with women ineligible for these analyses. Eligibility was not associated with prior hormone use at baseline. The eligible population was 48.0% white, 18.8% African American, 17.9% Japanese, and 15.3% Chinese. Half of the women had at least a college education and approximately one-third found it somewhat or very hard to pay for basics. Forty percent were overweight or obese. Twelve percent had taken HT, but three-quarters had used oral contraceptives before enrolling in the study. Only 11.9% were current smokers.
The 1,145 eligible women contributed a total of 4,712 women-years of observation after the start of the early MT. The FMP was observed in 428 (37.4%) of the 1,145 women, 44 (3.6%) were censored due to hysterectomy, 152 (13.3%) because of HT use or chemotherapy, whereas 521 were still bleeding at the time of their last observation.
Age at the onset of the MT
For age-at-onset ( Table 2 , column 1), a hazard ratio (HR) of greater than 1 indicated a greater likelihood to transition, that is, a younger age at the start of the MT, whereas an HR of less than 1 indicated an older age at MT onset. Women who were overweight (HR ¼ 0.77, 95% CI: 0.66-0.90) started the MT later than women who were normal weight, but the HR for obese women was not significant (HR ¼ 0.88, 95% CI: 0.74-1.03, P ¼ 0.11). Current smokers were younger at the onset of the MT (HR ¼ 1.46, 95% CI: 1.21-1.76) than nonsmokers with an adjusted median age-at-onset of the MT of 46.05 years for current smokers compared with 47.27 years for nonsmokers (Fig. 1) .
Duration of the MT
For duration models ( Table 2 , columns 2 and 3), an HR greater than 1 represented faster progression through the stage and thus a shorter duration than the referent group. An HR less than 1 represented slower progression and thus a longer duration than the referent group. Age at the onset of the early MT was strongly associated with duration of the early MT and total MT. Women in the youngest age-at-onset quartile had a longer early MT (HR ¼ 0.37, 95% CI: 0.30-0.46, P < 0.001) and longer total MT (HR ¼ 0.30, 95% CI: 0.22-0.40, P < 0.001), whereas women who were in the oldest age-atonset quartile had a shorter duration of the early MT (HR ¼ 1.32, 95% CI: 1.10-1.60, P < 0.001) and total MT (HR ¼ 1.80, 95% CI: 1.40-2.31, P < 0.001) than women in quartile 3. Results were similar for the duration of the late MT. Compared with women in age-at-onset quartile 3, women in the youngest quartile at the onset of the late MT had a longer late MT stage (HR ¼ 0.51, 95% CI: 0.39-0.68, P < 0.001), whereas those in the oldest quartile had a shorter late MT stage (HR ¼ 1.29, 95% CI: 1.00-1.72, P ¼ 0.05).
Adjusted for race/ethnicity, BMI, short menstrual cycles at baseline, unpredictable menstrual cycles during ages 25 to 30 e HR >1 corresponds to shorter duration and <1 corresponds to longer duration than referent group. f P for trend <0.01.
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TABLE 2. Adjusted HRs for predictors of age at onset of the MT and duration of the MT, Study of Women's Health Across the Nation menstrual calendars (four sites, n ¼ 1,145)
FIG. 1.
Adjusted distribution of age at onset of the menopausal transition by baseline smoking status, Study of Women's Health Across the Nation (SWAN). Distributions adjusted for race/ethnicity, body mass index, short menstrual cycles at baseline, unpredictable menstrual cycles during age 25 to 30, and baseline education. Current smokers had an earlier age at the onset of the menopausal transition than nonsmokers (P < 0.001).
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FIG. 2. Adjusted distributions of duration of the early menopausal transition (A), late menopausal transition (B)
, and total menopausal transition (C) by quartiles of age at the onset of the stage, Study of Women's Health Across the Nation (SWAN). Distributions adjusted for race/ethnicity, body mass index, short menstrual cycles at baseline, unpredictable menstrual cycles during age 25 to 30, current smoking status, and baseline education. Women in the youngest quartile had longer duration of the early menopausal transition (P < 0.001), late menopausal transition (P < 0.001), and total menopausal transition (P < 0.001) than women in the older quartiles.
PARAMSOTHY ET AL
years, current smoking status, and baseline education, for the early MT stage, the adjusted median duration was 5.14 years, 3.27 years, 2.18 years, and 1.68 years for the first, second, third, and fourth age-at-onset quartiles, respectively, P < 0.001 ( Fig. 2A) . For the late MT stage and the total MT, the adjusted median durations were 3.42 years, 2.55 years, 2.47 years, and 2.15 years and 8.57 years, 6.84 years, 5.08 years, and 4.37 years for the first, second, third, and fourth age-at-onset quartiles, respectively, P < 0.001 (Fig. 2B, C) .
African American women had longer total MTs (HR ¼ 0.68, 95% CI: 0.50-0.92, P ¼ 0.012) than white women. Current smokers had a shorter duration of the early MT and a shorter duration of the total MT (HR ¼ 1.66, 95% CI: 1.33-2.08, P < 0.001; HR ¼ 1.87, 95% CI: 1.37-2.54, P < 0.001, respectively). BMI was not associated with the duration of the MT or its stages. Women whose usual menstrual cycles at the start of the study were short (25 d) had a shorter late and total MT (HR ¼ 1.29, 95% CI: 1.02-1.61, P ¼ 0.030; HR ¼ 1.39, 95% CI: 1.12-1.74, P ¼ 0.003). Women who had unpredictable menstrual cycles at age 25 to 30 had a longer early MT (HR ¼ 0.76, 95% CI: 0.60-0.95, P ¼ 0.148). Women who were high school graduates or had less education had a shorter early MT (HR ¼ 1.25, 95% CI: 1.04-1.51, P ¼ 0.021) than women who had more education.
It is possible that the onset of the early and/or late transitions may have been more likely to have occurred before enrollment in women who were older at enrollment than in women who were younger at enrollment, thus biasing the results. We therefore reran the analysis including only those women who were age 45 years or less at enrollment. Although the smaller sample size reduced the statistical power, the HRs for age at the onset of each transition stage were consistent with younger age at the start of the stage remaining associated with longer duration of the transition (data not shown).
DISCUSSION
This multiracial/ethnic cohort study used prospectively collected menstrual calendars from over 1,000 participants to assess factors associated with the age at which the MT begins and its duration. Age-at-onset was the strongest predictor of MT duration: the length of each MT stage was shorter in women who were older at the onset of the MT. Smoking was associated with an earlier onset and shorter duration of MT, whereas greater BMI was associated with a later onset of the MT but not with its duration. African Americans experienced longer duration than whites.
These results are consistent with both the landmark TREMIN menstrual calendar study in which women who were younger at the onset of the MT had a longer MT 19 and the questionnaire-based Massachusetts Women's Health Study in which older age at the onset of the MT was associated with shorter perimenopause. 24 Notably, longer duration of hot flashes have also been associated with younger age at onset in SWAN. 34 These data provide valuable information for women and clinicians regarding factors that alter the expected duration of the transition which may assist in decision making regarding symptom management and choice of interventions to address abnormal bleeding as well as screening for bone loss and adverse changes in cardiovascular risk. An earlier onset of the MT would suggest a longer duration of possible intervention for perimenopausal health concerns, whereas a late onset could permit the option of observation for an expected briefer duration of symptoms or abnormal bleeding. A woman who is aware that her menopausal symptoms are likely to be prolonged may be more likely to seek more effective forms of treatment for her symptoms, rather than passively await their decrease over time. Also, a frequent clinical question that women ask is when they may safely stop using contraception. A woman who has an early onset of her MT might inappropriately assume that she is no longer fertile before that is truly the case. Knowing that her transition may be prolonged will help her avoid an unexpected pregnancy.
Smoking affected both the timing and duration of the MT. Others have reported that smokers have an earlier age at FMP. [7] [8] [9] [10] [11] 17 In the Massachusetts Women's Health Study, smokers had an earlier age at MT onset and a shorter overall MT duration. 24 In the Penn-Ovarian Aging Study, smokers had an earlier onset of each stage. 25 We found smokers to have a younger age-at-onset as well as a shorter early MT, leading to a shorter duration of the MT. These findings provide further evidence of the cytotoxic effect of smoking on the ovaries leading to accelerated ovarian aging. 35 Several studies have reported that BMI is not related to age at FMP. 8, 9, 12, 13, 36 In the SWAN cross-sectional survey, BMI was not associated with age at FMP, 9 but a longitudinal analysis of the SWAN cohort observed a later age at FMP among higher weight women. 17 Our findings suggest that BMI does influence the onset of the MT. Premenopausal women can be misclassified as in the MT because of the increased frequencies of menstrual irregularity in women who are obese 37 ; however, obesity has been associated with an earlier entry into the perimenopause in one other study 26 and with earlier entry into the late reproductive stage but not later stages in another. 25 We found that BMI was associated with older age at the onset of the MT, but not with duration of the MT after adjusting for age at MT onset.
Women with longer average cycle length during their reproductive years have a later age at menopause, 14, 16 whereas women with shorter cycles have an earlier age at menopause. 15 We found that short cycles at baseline were associated with a shorter duration of the late and total MT. Shorter cycles may simply mark the onset of early transition; however, they may also suggest more frequent recruitment of follicles and possible accelerated depletion of the primordial reserve. In contrast, we found reporting unpredictable menstrual cycles at ages 25 to 30 years was associated with a longer early MT stage. Irregular menstrual cycles between ages 20 to 35 years have been associated with a later age at FMP. 7 Although race/ethnicity and age at menopause have been inconsistently associated, 7,9,17 we found African American
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women had a longer duration of the MT than white women. Although it did not reach statistical significance, we found African American women tended to have an earlier age-atonset of the MT. Two other studies have reported an earlier age-at-MT-onset among African Americans. 25, 26 This study provides additional evidence that low socioeconomic position may adversely affect menstrual function. 38, 39 In SWAN, women with less education had an earlier age at FMP. 9, 17 We found that less education was associated with a shorter early MT. Although it is difficult to link plausibly educational level directly to ovarian function, it is a proxy for socioeconomic status (which was previously found in SWAN to account for racial/ethnic differences in age at FMP) 17 and thus for increased chronic stress and poorer nutrition. Oxidative stress 40 and diet 41 have been associated with reduced ovarian function, but a direct association with MT duration remains speculative.
This study had some limitations. Left truncation, which occurred in SWAN because participants were excluded if they had had their FMP, no period for 3 months or hysterectomy, may have biased our results by selectively excluding women with earlier or shorter transitions. When we conducted sensitivity analyses including only women enrolled before age 45 years our results were, however, similar. Similarly, left censoring, that is when the MT started before the enrollment, was another potential source of bias. Women with polycystic ovarian syndrome who experience irregular cycles were more likely to be excluded, which may have influenced findings related to BMI. 42 Selection bias also may have been present as eligibility rates for this analysis differed by race/ethnicity, body size, and socioeconomic status.
Despite these limitations, this large multiracial/ethnic prospective study is the first of which we are aware to evaluate duration of each MT stage as defined by the STRAWþ10 criteria. Notably, earlier age-at-onset of the MT was associated with a longer transition, important information for guiding women regarding their likely menopausal experience. This finding provides a strong rationale for developing improved markers of the onset of the early transition, including evaluation of an inexpensive, validated, reliable antimüllerian hormone assay and an improved questionnaire for assessing bleeding markers of the early transition. 31 Both tools would prove useful for forecasting duration of MT stages and permitting better management of common symptoms such as hot flashes, irregular bleeding, and sleep disturbances, all of which impair quality of life and are amenable to a variety of effective treatments. 2 Similarly, improved identification of MT onset with knowledge of the likely duration of each stage would assist decision making regarding timing of screening and interventions to address bone loss and change in cardiovascular risk during the late MT. 4, 5 CONCLUSIONS This large multiracial/ethnic prospective study is among the first to evaluate duration of the MT stages as defined by the STRAWþ10 criteria, using daily menstrual calendars, and provided data on factors associated with duration of MT stages. Our results provide further evidence of the cytotoxic effects of smoking on the reproductive system and its consequences for reproductive aging. High BMI seemed to delay MT onset, but had little influence on the duration of the transition beyond its influence on age when the transition starts. Most notably, duration of the MT was largely influenced by the age at which it began, a key finding for women and their clinicians regarding factors that may alter the expected duration of the transition and assist in decision making regarding symptom management and choice of interventions to address abnormal bleeding as well as screening for bone loss and adverse changes in cardiovascular risk.
